PRLD/ 11/04/2025 · 11:28 AM Prelude Therapeutics Refocuses Strategy to Advance Key Cancer Programs Prelude Therapeutics streamlines its oncology pipeline — prioritizing JAK2V617F and KAT6A programs, pausing SMARCA2, and securing major funding through an Incyte partnership.